Simply administering extrinsic FGF or VEGF to improve pulmonary vascular lesions and hypoxia, or administering FGFR or VEGFR antagonists to delay the progression of liver cirrhosis seems much more inappropriate as each may exacerbate the situation of the other. Here, VEGFA is linked to cirrhosis of liver.